Gene expression and response prediction to amisulpride in the OPTiMiSE first episode psychoses.

ABSTRACT: A fundamental shortcoming in the current treatment of schizophrenia is the lack of valid criteria to predict who will respond to antipsychotic treatment. The identification of blood-based biological markers of the therapeutic response would enable clinicians to identify the subgroup of patients in whom conventional antipsychotic treatment is ineffective and offer alternative treatments. As part of the Optimisation of Treatment and Management of Schizophrenia in Europe (OPTiMiSE) programme, we conducted an RNA-Seq analysis on 188 subjects with first episode psychosis, all of whom were subsequently treated with amisulpride for 4 weeks. We compared gene expression on total RNA from patients' blood before and after treatment and identified 32 genes for which the expression changed after treatm

SUBMITTER: Troudet R 

PROVIDER: S-EPMC7421408 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature